Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis Receptos, 27 Jan 2011 Accessed on 1 Nov 2012 from http://www.receptos.com/pdfs/Receptos-S1P1-Aimed-at-MS-1-27-11.pdf.
Spin-offs: Meet the structure specialists C. Drahl, Chemical & Engineering News, 14 Mar 2011 Accessed on 10 Nov 2011 from http://cen.acs.org/articles/89/i11/Spin-Offs-Meet-Structure-Specialists.html.
Receptos to deliver scientific presentation at Digestive Disease Week 2012 about the therapeutic role of RPC1063 in inflammatory bowel disease Market Watch, The Wall Street Journal, 18 May 2012 Accessed on 21 May 2012 from http://www.marketwatch.com/story/receptos-to-deliver-scientific-presentation-at-digestive-disease-week-2012-about-the-therapeutic-role-of-rpc1063-in-inflammatory-bowel-disease-2012-05-18.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis Receptos, 22 Oct 2012 Accessed on 1 Nov 2012
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients ClinicalTrials.gov, 4 Oct 2012 Accessed on 1 Nov 2012 from http://www.clinicaltrials.gov/ct2/show/NCT01628393?term=rpc1063.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Receptos, 9 Oct 2012 Accessed on 1 Nov 2012 from http://www.receptos.com/pdfs/Receptos-100912.pdf.
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis Receptos, 4 Jan 2013 Accessed on 7 Jan 2013 from http://www.receptos.com/pdfs/Receptos-010413.pdf.
Receptos provides update on progress of lead product candidate RPC1063 Globe Newswire, 5 Jun 2013 Accessed on 8 Jun 2013 from http://www.globenewswire.com/news-release/2013/06/05/552208/10035250/en/Receptos-Provides-Update-on-Progress-of-Lead-Product-Candidate-RPC1063.html.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063 Receptos, 13 Aug 2013 Accessed on 18 Aug 2013 from http://files.shareholder.com/downloads/AMDA-1S4LZL/2640831814x0x684370/d80a702c-e93e-448c-b54d-fdfa7d95d530/RCPT_News_2013_8_13_General_Releases.pdf.
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Receptos, 2 Oct 2013 Accessed on 5 Oct 2013 from http://files.shareholder.com/downloads/AMDA-1S4LZL/2640831814x0x694353/4fc7ef11-ffde-4faf-8f53-413d8641d5ba/RCPT_News_2013_10_2_General_Releases.pdf.
Receptos reports third quarter 2013 financial results Market Watch, The Wall Street Journal, 30 Oct 2013 Accessed on 5 Nov 2013 from http://www.marketwatch.com/story/receptos-reports-third-quarter-2013-financial-results-2013-10-30?reflink=MW_news_stmp.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis Receptos, 5 Dec 2013 Accessed on 10 Dec 2013 from http://files.shareholder.com/downloads/AMDA-1S4LZL/2640831814x0x711547/62fc7daf-9c37-4678-8834-36d67b0e4435/RCPT_News_2013_12_5_General_Releases.pdf.
Receptos begins enrollment of Phase 3 trial of RPC1063 in relapsing multiple sclerosis Receptos, 6 Jan 2014 Accessed on 10 Jan 2014 from http://files.shareholder.com/downloads/AMDA-1S4LZL/2640831814x0x716594/302f0fef-0e7a-4c43-94ea-5e43b315b05f/RCPT_News_2014_1_6_General_Releases.pdf.
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting Receptos, 28 Apr 2014 Accessed on 19 May 2014 from http://files.shareholder.com/downloads/AMDA-1S4LZL/2640831814x0x747867/a73b7471-c72f-414d-a4d8-fcb9bf333e5c/RCPT_News_2014_4_28_General_Releases.pdf.
Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis Receptos, 9 Jun 2014 Accessed on 12 Jun 2014 from http://files.shareholder.com/downloads/AMDA-1S4LZL/2640831814x0x760970/349603dc-5102-4d27-abf4-95d16c92b97f/RCPT_News_2014_6_9_General_Releases.pdf.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials Oakes K, HCP Live, 14 Sep 2014 Accessed on 16 Sep 2014 from http://www.hcplive.com/conferences/2014-ectrims/Novel-Immune-Regulator-Shows-Promise-as-MS-Therapy-in-Clinical-Trials.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis Receptos, 27 Oct 2014 Accessed on 4 Nov 2014 from http://ir.receptos.com/releasedetail.cfm?ReleaseID=878411.
Novel MS Drugs Advance Gever J, MedPage Today, 4 Nov 2014 Accessed on 11 Nov 2014 from http://www.medpagetoday.com/Neurology/MultipleSclerosis/48404.
Phase 3 Study of RPC1063 in Relapsing MS ClinicalTrials.gov, 11 Dec 2014 Accessed on 23 Dec 2014 from https://www.clinicaltrials.gov/ct2/show/NCT02294058.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis Receptos, 22 Dec 2014 Accessed on 23 Dec 2014 from http://files.shareholder.com/downloads/AMDA-1S4LZL/2640831814x0x800406/780DD475-5873-4D67-A6C7-06C12EC2397B/RCPT_News_2014_12_22_General_Releases.pdf.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K Receptos, 21 Feb 2015 Accessed on 3 Mar 2015 from http://ir.receptos.com/secfiling.cfm?filingid=1193125-15-57164&cik=1463729.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis Receptos, 1 Apr 2015 Accessed on 14 Apr 2015 from http://ir.receptos.com/releasedetail.cfm?ReleaseID=904448.
Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases Celgene, 14 Jul 2015 Accessed on 28 Jul 2015 from http://ir.celgene.com/releasedetail.cfm?ReleaseID=922090.
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW, et al. Lancet Neurol. 2016 Feb 12. PMID: 26879276. Abstract
Disease Suppression Persists With Ozanimod at 72 Weeks in MS Helwick C, Medscape, 20 Feb 2016 Accessed on 23 Feb 2016 from http://www.medscape.com/viewarticle/859170#vp_1.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity. Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, Desale HG, Timony GA, Martinborough E, Rosen H, et al. Br J Pharmacol. 2016 Mar 15. PMID: 26990079. Abstract